Physician profile
Jacob Cherian
NPI 1003973637
$6,144.68
in general payments reported to CMS, 2019-2025
21 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $620 · 2021: $1,109 · 2022: $869 · 2023: $2,285 · 2024: $656 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,911 · Food and Beverage: $1,320 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,910.58 |
| Food and Beverage | $1,319.71 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imperative Care, INC | $2,068.95 | 2023-2024 | Zoom 88-T Large Distal Platform |
| Kowa Pharmaceuticals America, INC. | $677.90 | 2019-2023 | Livalo, Seglentis |
| Abbvie INC. | $528.95 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Allergan, INC. | $367.71 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $364.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $358.74 | 2019-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $336.69 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $221.01 | 2022 | |
| Glaxosmithkline, LLC. | $218.68 | 2019-2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $198.68 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $184.44 | 2020-2024 | |
| Amarin Pharma, INC. | $139.14 | 2019-2022 | |
| Astellas Pharma US INC | $127.76 | 2021-2023 | Veozah |
| Merck Sharp & Dohme LLC | $93.74 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $88.69 | 2023-2024 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $34.09 | 2021 | |
| Abbott Laboratories | $33.68 | 2021 | |
| Globus Medical, INC. | $31.10 | 2025 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.51 | 2025 | Jardiance |
| Mylan Specialty L.P. | $22.21 | 2019 | |
| Medicure Pharma INC. | $20.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.